hepatocellular carcinoma
Conditions
Interventions
miriplatin 60mg cisplatin 50mg ethyl ester of iodinated poppy-seed oil fatty acid 6ml
Sponsors
Southern TOHOKU General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Substantial enhancement during arterial phase followed by a washout with corona-like peripheral enhancement in equilibrium phase by dynamic CT 2)4 weeks from the prior therapy 3)Anticipated survival is less than 3 months 4)Child A or B 5)Adequate baseline organ and marrow function as defined below: hemoglobin: >=9.5 g/dL WBC count: >=3,000/mm3 platelet count: >=50,000 mm3 total bilirubin: =<3.0 mg/dL AST(GOT): =<ULN x 5 ALT(GPT): =<ULN x 5 albumin >=2.5g/dl serum creatinine: =<1.5 mg/dL 6)ECOG performance status (PS) 0-1 7)Written informed consent
Exclusion criteria
Exclusion criteria: 1)History of hypersensitivity reaction 2)Other severe complications, such as uncontrollable diabetes or heart failure, renal insufficiency, liver failure 3)Active another cancer 4)Pregnant or possibility pregnancy or nursing woman 5) Physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| anti-tumor effect | — |
Countries
Japan
Contacts
Public ContactKoichi Hamada
Southern TOHOKU General Hospital Department of Gastroenterology
Outcome results
None listed